SCHEMBL434780

SCHEMBL434780

CCCC(CC(=O)OC)c1ccc(OCc2ccc(OC/C(=N\OC)c3ccccc3)cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 4/20 0.56
MAOB P27338 1/20 0.43
ALDH1A1 P00352 2/20 0.40
HTT P42858 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MAPT P10636 2/20 0.40
GAA P10253 1/20 0.40
RAB9A P51151 1/20 0.40
FNTA P49354 1/20 0.40
FNTB P49356 1/20 0.40
PRKCA P17252 1/20 0.39
PRKCD Q05655 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
RXRA P19793 1/20 0.39
RXRB P28702 1/20 0.39
HDAC3 O15379 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39
NCOR2 Q9Y618 1/20 0.39
ALOX5 P09917 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL434781 1.00 FFAR1 (0.56) FFAR1MAOBALDH1A1HTTSMN1; SMN2
SCHEMBL435951 0.92 FFAR1 (0.61) FFAR1ALDH1A1HTTSMN1; SMN2MAPT
SCHEMBL435952 0.92 FFAR1 (0.61) FFAR1ALDH1A1HTTSMN1; SMN2MAPT
SCHEMBL10260680 0.86 FFAR1 (0.60) FFAR1MAOBALDH1A1HTTSMN1; SMN2
SCHEMBL434797 0.86 FFAR1 (0.60) FFAR1MAOBALDH1A1HTTSMN1; SMN2
SCHEMBL434798 0.86 FFAR1 (0.60) FFAR1MAOBALDH1A1HTTSMN1; SMN2
SCHEMBL22668454 0.84 FFAR1 (0.65) FFAR1ALDH1A1HTTSMN1; SMN2MAPT
SCHEMBL15239589 0.83 FFAR1 (0.56) FFAR1MAOBALDH1A1HTTSMN1; SMN2
SCHEMBL10259320 0.83 FFAR1 (0.56) FFAR1MAOBALDH1A1HTTSMN1; SMN2
SCHEMBL435029 0.82 FFAR1 (0.59) FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2595952-B1 AGONISTS OF GPR40 CONNEXIOS LIFE SCIENCES PVT LTD (IN) 2020-11-18 EP disclosed
US-9278915-B2 Agonists of GPR40 CONNEXIOS LIFE SCIENCES PVT LTD (IN) 2016-03-08 US disclosed
US-9278915-B2 Agonists of GPR40 CONNEXIOS LIFE SCIENCES PVT LTD (IN) 2016-03-08 US disclosed
US-9278915-B2 Agonists of GPR40 CONNEXIOS LIFE SCIENCES PVT LTD (IN) 2016-03-08 US disclosed
US-20130237571-A1 AGONISTS OF GPR40 Conexios Life Sciences PVT. LTD. (IN) 2013-09-12 US disclosed
US-20130237571-A1 AGONISTS OF GPR40 Conexios Life Sciences PVT. LTD. (IN) 2013-09-12 US disclosed
US-20130237571-A1 AGONISTS OF GPR40 Conexios Life Sciences PVT. LTD. (IN) 2013-09-12 US disclosed
WO-2012011125-A1 AGONISTS OF GPR40 CONNEXIOS LIFE SCIENCES PVT. LTD. (IN) 2012-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130237571-A1 AGONISTS OF GPR40 GPR65, GPR55, GPR68 FFAR1 24/4885MAOB 2832/4885ALDH1A1 2410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.